CORGENIX, INC.

Corgenix Medical Corporation is a CAP/CLIA-accredited in vitro diagnostics (IVD) company founded in 1990 and based in Broomfield, Colorado. The company specializes in developing, manufacturing, and commercializing diagnostic kits and operates as a Contract Development and Manufacturing Organization (CDMO) serving biotech companies, pharmaceutical firms, cancer centers, and academic laboratories. Corgenix offers over 50 diagnostic tests targeting immunology disorders, cardiovascular and vascular diseases, bone and joint disorders, and viral hemorrhagic diseases. Notable offerings include non-blood-based aspirin effect testing and multiple myeloma monitoring tools. The company provides comprehensive services across the IVD lifecycle: biomarker discovery, assay development, analytical and clinical validation, regulatory submissions, GMP manufacturing, quality control, and commercialization support. With an onsite CAP/CLIA laboratory, Corgenix supports clinical studies, trial management, physician-ordered patient testing, and research initiatives while maintaining strict regulatory compliance and GCP/GLP standards.